NEOCORE TECHNOLOGY CO., LTD. NeoCore Technology Co., Ltd. Stock
Equities
4131
TW0004131008
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.5 TWD | 0.00% |
|
+0.96% | +43.18% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 88.97M 2.75M 3.76M | Sales 2023 | 64.73M 2M 2.73M | Capitalization | 869M 26.84M 36.68M |
|---|---|---|---|---|---|
| Net income 2022 | -28M -865K -1.18M | Net income 2023 | -64M -1.98M -2.7M | EV / Sales 2022 | 5.21 x |
| Net Debt 2022 | 73.83M 2.28M 3.12M | Net cash position 2023 | 196M 6.07M 8.29M | EV / Sales 2023 | 10.4 x |
| P/E ratio 2022 |
-13.8
x | P/E ratio 2023 |
-11.8
x | Employees | 44 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 26.74% |
More Fundamentals
* Assessed data
More news
| 1 week | +0.96% | ||
| Current month | +0.96% | ||
| 1 month | -0.47% | ||
| 3 months | +24.02% | ||
| 6 months | +38.46% | ||
| Current year | +43.18% |
1 week
31.00
33.20
1 month
29.8033.25
Current year
22.0038.00
1 year
20.8038.00
3 years
13.1038.00
5 years
10.1750.71
10 years
10.1750.71
| Managers | Title | Age | Since |
|---|---|---|---|
Wen Tung Yang
CEO | Chief Executive Officer | - | 00-12-26 |
Yi Hsiang Li
DFI | Director of Finance/CFO | - | 04-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wen Tung Yang
CEO | Chief Executive Officer | - | 00-12-26 |
Tzu Ling Lin
BRD | Director/Board Member | - | 08-06-25 |
Shiang Chi Hu
BRD | Director/Board Member | 63 | 20-06-04 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-09 | 31.5 | 0.00% | 7,840 |
| 24-05-08 | 31.5 | +1.29% | 37,268 |
| 24-05-07 | 31.1 | -3.12% | 35,525 |
| 24-05-06 | 32.1 | -1.23% | 44,905 |
| 24-05-03 | 32.5 | -0.46% | 51,978 |
End-of-day quote Taipei Exchange, May 08, 2024
More quotes
NeoCore Technology Co Ltd is a Taiwan-based company mainly engaged in the research and development and production of biological detection chips and the trading of contact lenses of its subsidiaries, as well as the provision of related inspection and technology transfer services. The products include deoxyribonucleic acid / ribonucleic acid (DNA/RNA) sample preparation kits, polymerase chain reaction kits, rapid hybridization equipment, biochips, testing reagents, biological preparations, nucleic acid sequencing detection, biotechnology control hardware and software and related components, biomedical materials, and nutritional supplements. The products are mainly sold domestically and exported to Asia and Europe.
Calendar
2024-08-11
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +43.18% | 38.4M | |
| +73.46% | 12.41B | |
| -16.75% | 7.87B | |
| +5.93% | 6.37B | |
| +3.66% | 5.81B | |
| +13.79% | 5.36B | |
| +40.99% | 4.92B | |
| -19.73% | 4.02B | |
| -34.55% | 2.43B | |
| +0.74% | 2.02B |
- Stock Market
- Equities
- 4131 Stock